Capture_brand and logo.PNG
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
25 avr. 2023 07h00 HE | Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
25 avr. 2023 06h59 HE | Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
Capture_brand and logo.PNG
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
24 avr. 2023 16h01 HE | Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
02 nov. 2022 08h00 HE | Morphic Therapeutic
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter ...
Capture_brand and logo.PNG
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
25 oct. 2022 16h05 HE | Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Capture_brand and logo.PNG
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
24 oct. 2022 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
10 oct. 2022 08h00 HE | Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
Synlogic_Logo_Blue.png
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
06 sept. 2022 07h00 HE | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma, Inc. Announces Reverse Stock Split
25 août 2022 12h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Metacrine-Logo-R Transparent.png.png
Metacrine Reports Second-Quarter 2022 Results
09 août 2022 16h05 HE | Metacrine, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...